TRDAHealthcareMicro-Cap
Entrada Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Entrada Therapeutics, Inc. (TRDA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are TRDA insiders buying or selling?
Entrada Therapeutics, Inc. insiders reported 20 open-market buys ($40.0M) and 90 sells ($15.6M) across 110 Form 4 filings — a net buying position of $24.5M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 21, 2026)
Total Form 4 filings
110
SEC EDGAR
Insider filers
15
Insider buys (20)
$40.0M
Insider sells (90)
$15.6M
Insider sentiment
Net buyingNet insider flow of $24.5M in net buying. 1 insider buy in the last 90 days.
Recent TRDA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Bernhardt G Zeiher | Director | Purchase | 5.0K | $5.86 | $29.3K |
| May 4, 2026 | Natarajan Sethuraman | President, Research & Develop. | Sale | 25.9K | $15.39 | $398.8K |
| May 4, 2026 | Nathan J Dowden | President & COO | Sale | 15.0K | $15.33 | $230.0K |
| Apr 2, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 2.5K | $12.95 | $32.4K |
| Mar 11, 2026 | Nathan J Dowden | President & COO | Sale | 15.0K | $13.04 | $195.8K |
| Mar 11, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 16.5K | $13.01 | $214.4K |
| Mar 6, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 8.0K | $12.25 | $97.9K |
| Nov 24, 2025 | Kory James Wentworth | Chief Financial Officer | Sale | 8.9K | $9.98 | $88.9K |
| Nov 24, 2025 | Felix Baker | 10% Owner | Purchase | 28.9K | $9.07 | $261.8K |
| Nov 18, 2025 | Kush Parmar | Director, 10% Owner | Sale | 200.0K | $8.80 | $1.8M |
| Nov 18, 2025 | Scott M Rocklage | 10% Owner | Sale | 200.0K | $8.80 | $1.8M |
| Nov 12, 2025 | Felix Baker | 10% Owner | Purchase | 178.0K | $7.60 | $1.4M |
| Jul 11, 2025 | Kush Parmar | Director, 10% Owner | Sale | 27.0K | $7.50 | $202.6K |
| Jul 11, 2025 | Scott M Rocklage | 10% Owner | Sale | 27.0K | $7.50 | $202.6K |
| Jul 2, 2025 | Kush Parmar | Director, 10% Owner | Sale | 125.0K | $6.93 | $866.6K |
| Jul 2, 2025 | Scott M Rocklage | 10% Owner | Sale | 125.0K | $6.93 | $866.6K |
| Jun 18, 2025 | Peter S Kim | Director | Purchase | 50.0K | $14.63 | $731.7K |
| Mar 19, 2025 | Kory James Wentworth | Chief Financial Officer | Sale | 1.8K | $10.67 | $19.0K |
| Dec 12, 2024 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Sale | 44.7K | $20.51 | $917.1K |
| Dec 12, 2024 | Luke Evnin | 10% Owner | Sale | 44.7K | $20.51 | $917.1K |
| Dec 3, 2024 | Kory James Wentworth | Chief Financial Officer | Sale | 6.0K | $19.99 | $119.9K |
| Dec 3, 2024 | Natarajan Sethuraman | President, Research & Develop. | Sale | 15.9K | $20.18 | $320.6K |
| Nov 13, 2024 | Natarajan Sethuraman | President, Research & Develop. | Sale | 4.1K | $20.03 | $82.3K |
| Nov 13, 2024 | Kory James Wentworth | Chief Financial Officer | Sale | 8.6K | $19.98 | $172.6K |
| Nov 6, 2024 | Natarajan Sethuraman | President, Research & Develop. | Sale | 18.2K | $18.62 | $339.3K |
Showing the 25 most recent of 110 Form 4 filings for Entrada Therapeutics, Inc..
Most active TRDA insiders
- Dipal Doshi25 filings
- Kory James Wentworth21 filings
- Nathan J Dowden17 filings
- Natarajan Sethuraman10 filings
- Nerissa Kreher9 filings
Ask anything about TRDA insider activity
Use Trabud's AI agent to query Entrada Therapeutics, Inc.'s Form 4 history in plain English — "Show me TRDA CEO purchases this year" or compare it against any other ticker.
Open the AI agentTRDA insider trading FAQ
Are Entrada Therapeutics, Inc. insiders buying or selling?
Across 110 SEC Form 4 filings, Entrada Therapeutics, Inc. (TRDA) insiders reported 20 open-market purchases totaling $40.0M and 90 sales totaling $15.6M. That is a net buying position of $24.5M.
How many insiders trade TRDA stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Entrada Therapeutics, Inc.. The most recent filing was accepted on May 21, 2026.
Where does Trabud get TRDA insider trading data?
All TRDA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.